Sign in or create an account to add this stock to your watchlist.
About Biogen (NASDAQ:BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.42
Current Ratio3.23
Quick Ratio2.95
Price-To-Earnings
Trailing P/E Ratio12.82
Forward P/E Ratio11.70
P/E Growth1.64
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales4.81
Cash Flow$26.9971 per share
Price / Cash10.36
Book Value$59.56 per share
Price / Book4.70
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins23.54%
Return on Equity37.64%
Return on Assets20.32%
Miscellaneous
Employees7,300
Outstanding Shares211,010,000
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, April, 24th. The biotechnology company reported $6.05 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $5.93 by $0.12. The biotechnology company had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a return on equity of 37.64% and a net margin of 23.54%. The firm's revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $5.20 earnings per share. View Biogen's Earnings History.
When is Biogen's next earnings date?
What price target have analysts set for BIIB?
29 Wall Street analysts have issued 12 month price targets for Biogen's shares. Their predictions range from $262.15 to $425.00. On average, they expect Biogen's stock price to reach $353.9685 in the next year. View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
- 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
- 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO) and Atara Biotherapeutics (ATRA).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 53)
- Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
- Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
Has Biogen been receiving favorable news coverage?
Headlines about BIIB stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biogen earned a coverage optimism score of 0.19 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Biogen's major shareholders?
Biogen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.18%),
PRIMECAP MANAGEMENT COMPANY
(7.16%), Northern Trust Corp (1.36%), Massachusetts Financial Services Co. MA (0.98%), Summit Trail Advisors LLC (0.71%) and American Century Companies Inc. (0.56%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including PointState Capital LP, Franklin Resources Inc., Farallon Capital Management LLC, Sei Investments Co., Northern Trust Corp, Swiss National Bank, Woodford Investment Management Ltd and Swedbank. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Brian S Posner, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BlackRock Inc., Rockefeller Capital Management L.P., Old Mutual Global Investors UK Ltd., Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., American Century Companies Inc. and Candriam Luxembourg S.C.A.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $279.69.
How big of a company is Biogen?
Biogen has a market capitalization of $59.17 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biogen (NASDAQ:BIIB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $353.9685, suggesting that the stock has a possible upside of 26.56%. The high price target for BIIB is $425.00 and the low price target for BIIB is $262.15. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.69 | 2.69 | 2.73 | 2.66 |
| Ratings Breakdown: | 0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
9 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
22 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $353.9685 | $367.2222 | $369.7857 | $341.7037 |
| Price Target Upside: | 26.56% upside | 38.71% upside | 23.52% upside | 10.56% upside |
Biogen (NASDAQ:BIIB) Consensus Price Target History
Biogen (NASDAQ:BIIB) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Biogen (NASDAQ:BIIB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.29%
Institutional Ownership Percentage: 87.31%
Biogen (NASDAQ BIIB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/25/2018 | Alexander J Denner | Director | Buy | 48,000 | $269.91 | $12,955,680.00 | 10,029 |  |
| 2/27/2018 | Alfred Sandrock | EVP | Sell | 259 | $290.83 | $75,324.97 | 6,553 | |
| 2/20/2018 | Alfred Sandrock | EVP | Sell | 743 | $292.00 | $216,956.00 | 6,553 | |
| 2/15/2018 | Alfred Sandrock | EVP | Sell | 1,294 | $298.85 | $386,711.90 | 7,296 | |
| 1/9/2018 | Robert W Pangia | Director | Sell | 5,832 | $329.65 | $1,922,518.80 | 23,539 | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | 4,879 | |
| 11/29/2017 | Alexander J Denner | Director | Buy | 30,000 | $317.36 | $9,520,800.00 | 10,029 | |
| 7/25/2017 | Susan H Alexander | EVP | Sell | 4,974 | $290.01 | $1,442,509.74 | 22,258 | |
| 7/19/2017 | Susan H Alexander | EVP | Sell | 7,758 | $285.00 | $2,211,030.00 | 27,232 | |
| 6/9/2017 | Brian S Posner | Director | Sell | 1,084 | $256.31 | $277,840.04 | 6,330 | |
| 5/1/2017 | Michel Vounatsos | CEO | Buy | 1,402 | $271.35 | $380,432.70 | | |
| 4/27/2017 | Alexander J. Denner | Director | Buy | 73,858 | $278.50 | $20,569,453.00 | | |
| 4/25/2017 | Paul J Clancy | VP | Sell | 9,892 | $290.00 | $2,868,680.00 | 10,813 | |
| 4/3/2017 | Alfred Sandrock | CMO | Sell | 1,981 | $274.08 | $542,952.48 | 7,060 | |
| 3/13/2017 | Paul J Clancy | VP | Sell | 9,891 | $291.55 | $2,883,721.05 | 20,705 | |
| 2/27/2017 | Michel Vounatsos | CEO | Buy | 1,333 | $285.39 | $380,424.87 | | |
| 1/9/2017 | Robert W Pangia | Director | Sell | 5,450 | $295.39 | $1,609,875.50 | 22,078 | |
| 10/4/2016 | Adriana Karaboutis | EVP | Sell | 262 | $311.94 | $81,728.28 | 7,579 | |
| 10/3/2016 | Adriana Karaboutis | EVP | Sell | 380 | $313.00 | $118,940.00 | 7,172 | |
| 9/22/2016 | Caroline Dorsa | Director | Sell | 27,570 | $314.00 | $8,656,980.00 | 19,663 | |
| 7/21/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 54,779 | |
| 6/6/2016 | Adam Koppel | EVP | Sell | 555 | $290.00 | $160,950.00 | 2,402 | |
| 6/3/2016 | George A Scangos | CEO | Sell | 842 | $290.00 | $244,180.00 | 54,936 | |
| 6/1/2016 | George A Scangos | CEO | Sell | 3,855 | $289.74 | $1,116,947.70 | 56,265 | |
| 5/25/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 59,633 | |
| 5/2/2016 | George A Scangos | CEO | Sell | 487 | $274.74 | $133,798.38 | 59,790 | |
| 4/6/2016 | Adam Koppel | EVP | Sell | 102 | $275.00 | $28,050.00 | 1,848 | |
| 4/6/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 60,277 | |
| 4/1/2016 | George A Scangos | CEO | Sell | 487 | $258.83 | $126,050.21 | 60,434 | |
| 3/1/2016 | George A Scangos | CEO | Sell | 487 | $261.37 | $127,287.19 | 60,921 | |
| 2/25/2016 | Adriana Karaboutis | EVP | Sell | 84 | $261.90 | $21,999.60 | 8,127 | |
| 2/25/2016 | Alfred Sandrock | CMO | Sell | 183 | $261.90 | $47,927.70 | 7,990 | |
| 2/17/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 722 | $256.16 | $184,947.52 | 7,990 | |
| 2/17/2016 | George A Scangos | CEO | Sell | 487 | $256.16 | $124,749.92 | 59,848 | |
| 2/9/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 852 | $246.54 | $210,052.08 | 7,740 | |
| 12/4/2015 | Alfred Sandrock | CMO | Sell | 441 | $277.00 | $122,157.00 | 7,740 | |
| 10/23/2015 | Alexander J Denner | Director | Buy | 310,000 | $277.47 | $86,015,700.00 | 7,890 | |
| 7/27/2015 | Stelios Papadopoulos | Director | Buy | 10,000 | $304.88 | $3,048,800.00 | | |
| 6/19/2015 | Douglas E Williams | EVP | Sell | 3,841 | $410.00 | $1,574,810.00 | | |
| 6/1/2015 | George A Scangos | CEO | Sell | 1,362 | $398.87 | $543,260.94 | | |
| 4/1/2015 | George A Scangos | CEO | Sell | 1,362 | $423.20 | $576,398.40 | | |
| 3/25/2015 | John Cox | EVP | Sell | 12,010 | $449.06 | $5,393,210.60 | | |
| 3/20/2015 | Eric K Rowinsky | Director | Sell | 11,667 | $475.00 | $5,541,825.00 | | |
| 3/19/2015 | Eric K Rowinsky | Director | Sell | 2,333 | $436.14 | $1,017,514.62 | | |
| 3/17/2015 | Eric K Rowinsky | Director | Sell | 4,667 | $425.45 | $1,985,575.15 | | |
| 3/10/2015 | Robert W Pangia | Director | Sell | 3,625 | $413.40 | $1,498,575.00 | | |
| 3/2/2015 | Alfred Sandrock | SVP | Sell | 3,174 | $409.49 | $1,299,721.26 | | |
| 2/17/2015 | Steven H Holtzman | EVP | Sell | 2,128 | $389.11 | $828,026.08 | | |
| 2/10/2015 | Alfred Sandrock | SVP | Sell | 1,143 | $398.11 | $455,039.73 | | |
| 2/2/2015 | Kenneth Dipietro | EVP | Sell | 1,656 | $389.03 | $644,233.68 | | |
| 12/15/2014 | Spyridon Artavanis-Tsakonas | SVP | Sell | 1,981 | $346.50 | $686,416.50 | | |
| 12/2/2014 | Steven H Holtzman | EVP | Sell | 1,749 | $335.65 | $587,051.85 | | |
| 11/11/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.00 | $577,500.00 | | |
| 11/3/2014 | George A Scangos | CEO | Sell | 1,128 | $320.78 | $361,839.84 | | |
| 10/1/2014 | George A Scangos | CEO | Sell | 1,127 | $330.97 | $373,003.19 | | |
| 10/1/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.97 | $579,197.50 | | |
| 8/1/2014 | George A Scangos | CEO | Sell | 1,128 | $332.93 | $375,545.04 | | |
| 7/16/2014 | George A Scangos | CEO | Sell | 12,316 | $312.37 | $3,847,148.92 | | |
| 5/19/2014 | Steven Holtzman | EVP | Sell | 1,221 | $289.15 | $353,052.15 | 5,749 | |
| 5/1/2014 | George Scangos | CEO | Sell | 2,123 | $285.56 | $606,243.88 | 24,019 | |
| 4/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $291.00 | $355,311.00 | 6,970 | |
| 4/1/2014 | George Scangos | CEO | Sell | 2,123 | $308.42 | $654,775.66 | 26,142 | |
| 4/1/2014 | Robert Pangia | Director | Sell | 6,250 | $308.42 | $1,927,625.00 | 14,003 | |
| 3/31/2014 | Brian Posner | Director | Sell | 3,000 | $296.76 | $890,280.00 | 6,435 | |
| 3/20/2014 | Caroline Dorsa | Director | Sell | 10,000 | $348.88 | $3,488,800.00 | 14,468 | |
| 3/19/2014 | Douglas Williams | EVP | Sell | 3,505 | $352.29 | $1,234,776.45 | 7,976 | |
| 3/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $334.83 | $408,827.43 | 8,191 | |
| 3/11/2014 | Stuart Kingsley | EVP | Sell | 8,428 | $336.83 | $2,838,803.24 | 3,511 | |
| 3/3/2014 | George Scangos | CEO | Sell | 2,942 | $335.79 | $987,894.18 | 54,389 | |
| 2/26/2014 | Alfred Sandrock | SVP | Sell | 1,048 | $342.17 | $358,594.16 | 21,407 | |
| 2/18/2014 | Steven Holtzman | EVP | Sell | 1,222 | $327.90 | $400,693.80 | 9,412 | |
| 2/13/2014 | Kenneth Dipietro | EVP | Sell | 1,290 | $316.81 | $408,684.90 | | |
| 2/11/2014 | Alfred Sandrock | SVP | Sell | 2,085 | $314.31 | $655,336.35 | 13,667 | |
| 2/11/2014 | George Scangos | CEO | Sell | 2,456 | $314.31 | $771,945.36 | 52,961 | |
| 2/4/2014 | Kenneth Dipietro | EVP | Sell | 1,655 | $299.01 | $494,861.55 | | |
| 1/21/2014 | Eric Rowinsky | Director | Sell | 2,020 | $310.09 | $626,381.80 | 10,440 | |
| 1/15/2014 | Lynn Schenk | Director | Sell | 1,000 | $297.48 | $297,480.00 | 3,325 | |
| 1/8/2014 | William Young | Director | Sell | 15,000 | $285.11 | $4,276,650.00 | 18,509 | |
| 1/6/2014 | Robert Pangia | Director | Sell | 6,250 | $278.03 | $1,737,687.50 | 14,003 | |
| 12/2/2013 | Lynn Schenk | Director | Sell | 1,000 | $291.71 | $291,710.00 | 3,325 | |
| 11/22/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $288.00 | $1,152,000.00 | 8,710 | |
| 11/1/2013 | George A Scangos | CEO | Sell | 2,239 | $245.57 | $549,831.23 | | |
| 11/1/2013 | Lynn Schenk | Director | Sell | 1,000 | $245.00 | $245,000.00 | | |
| 10/22/2013 | Alfred Sandrock | SVP | Sell | 15,030 | $250.11 | $3,759,153.30 | | |
| 9/18/2013 | Paul Clancy | CFO | Sell | 26,785 | $245.00 | $6,562,325.00 | 7,087 | |
| 9/17/2013 | Steven Holtzman | EVP | Sell | 3,501 | $238.98 | $836,668.98 | 4,885 | |
| 9/16/2013 | Paul Clancy | CFO | Sell | 99,030 | $238.27 | $23,595,878.10 | 7,087 | |
| 9/16/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $238.03 | $952,120.00 | 8,710 | |
| 9/3/2013 | George Scangos | CEO | Sell | 2,239 | $214.40 | $480,041.60 | 43,522 | |
| 8/26/2013 | Douglas Williams | EVP | Sell | 4,368 | $211.35 | $923,176.80 | 4,571 | |
| 8/1/2013 | George A Scangos | CEO | Sell | 2,239 | $218.82 | $489,937.98 | | |
| 7/16/2013 | George A Scangos | CEO | Sell | 2,239 | $223.94 | $501,401.66 | | |
| 6/14/2013 | Alexander J Denner | Director | Sell | 2,900 | $212.00 | $614,800.00 | | |
| 6/11/2013 | Brian S Posner | Director | Sell | 2,020 | $219.62 | $443,632.40 | | |
| 6/10/2013 | Lynn Schenk | Director | Sell | 2,000 | $225.82 | $451,640.00 | | |
| 6/3/2013 | George A Scangos | CEO | Sell | 1,598 | $234.16 | $374,187.68 | | |
| 6/3/2013 | Stephen A Sherwin | Director | Sell | 12,825 | $233.26 | $2,991,559.50 | | |
| 5/28/2013 | Robert W Pangia | Director | Sell | 5,900 | $237.23 | $1,399,657.00 | | |
| 12/27/2012 | Alexander J Denner | Director | Sell | 7,980 | $148.62 | $1,185,987.60 | | |
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
finance.yahoo.com - May 22 at 5:10 PM |
| Vivus Stock Rose 60% Last Week
finance.yahoo.com - May 22 at 8:17 AM |
| BlueBird Bio Stock Jumps over 6% on May 17
finance.yahoo.com - May 18 at 8:31 AM |
| Amgen Stock Rises over 2% on Drug Approvals
finance.yahoo.com - May 18 at 8:31 AM |
 | No FDA Seal of Approval for These Big Biotechs
www.wsj.com - May 17 at 6:49 PM |
| Biogen, Shire called out by FDA for ‘gaming’ generic access rule
finance.yahoo.com - May 17 at 6:49 PM |
 | Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion
www.americanbankingnews.com - May 15 at 4:40 AM |
| Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer?
finance.yahoo.com - May 14 at 5:22 PM |
| $5.29 EPS Expected for Biogen (BIIB) This Quarter
www.americanbankingnews.com - May 13 at 3:19 AM |
| Biogen (BIIB) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 12 at 5:01 PM |
 | Positive prospects for biotech giants Biogen, Celgene, Gilead and Regeneron
www.cnbc.com - May 11 at 8:21 AM |
| Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects
finance.yahoo.com - May 11 at 8:21 AM |
| Cramer Remix: The one thing that’s keeping the market fro...
finance.yahoo.com - May 11 at 8:21 AM |
| Biogen (BIIB) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 10 at 3:00 PM |
 | 3 Stocks That Turned $10000 Into $1 Million
www.fool.com - May 9 at 5:37 PM |
| Our Free Research Report on Biogen and More Biotech Stocks
finance.yahoo.com - May 9 at 8:16 AM |
| Biogen (BIIB) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM |
| Mizuho Analysts Give Biogen (BIIB) a $423.00 Price Target
www.americanbankingnews.com - May 3 at 1:31 PM |
 | Bristol-Myers Squibb and Biogen Are the Pharmas Most Trusted by Doctors, Study Finds
www.prnewswire.com - May 2 at 5:39 PM |
 | Biogen Buy Signal: Alzheimer's Royalties Option
seekingalpha.com - May 2 at 5:39 PM |
| Biogen Director Denner Buys $13 Million in Stock
finance.yahoo.com - May 2 at 5:38 PM |
| Citigroup Trims Biogen (BIIB) Target Price to $290.00
www.americanbankingnews.com - May 2 at 11:11 AM |
| Biogen (BIIB) Raised to "B-" at TheStreet
www.americanbankingnews.com - May 2 at 10:25 AM |
 | BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment ...
www.reuters.com - May 1 at 5:20 PM |
| Biogen adding 150 jobs in RTP
finance.yahoo.com - May 1 at 5:20 PM |
| Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
www.fool.com - May 1 at 8:22 AM |
| Biogen will pay $50 million to reduce royalties on Alzheimer's disease drug
finance.yahoo.com - May 1 at 8:22 AM |
 | Insider Buys Of The Week: Apollo Global, Biogen And More
feeds.benzinga.com - April 29 at 10:42 AM |
| BRIEF-Biogen CEO Michel Vounatsos' Total Compensation For 2017 Was $13.7 Million
www.reuters.com - April 27 at 5:17 PM |
 | Here's Why 275% in Biogen Inc Stock Looks Realistic
investorplace.com - April 27 at 5:17 PM |
| Here’s Why 275% in Biogen Inc Stock Looks Realistic
investorplace.com - April 27 at 2:09 PM |
| Biogen (BIIB) Lifted to Hold at BidaskClub
www.americanbankingnews.com - April 27 at 12:13 PM |
| Biogen (BIIB) Director Alexander J. Denner Purchases 48,000 Shares
www.americanbankingnews.com - April 27 at 10:24 AM |
| Q3 2018 EPS Estimates for Biogen (BIIB) Boosted by SunTrust Banks
www.americanbankingnews.com - April 27 at 8:55 AM |
| Leerink Swann Weighs in on Biogen's Q3 2018 Earnings (BIIB)
www.americanbankingnews.com - April 27 at 8:55 AM |
| Biogen (BIIB) to Post Q2 2018 Earnings of $5.22 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - April 27 at 8:04 AM |
| Oppenheimer Brokers Cut Earnings Estimates for Biogen (BIIB)
www.americanbankingnews.com - April 27 at 8:04 AM |
| $3.23 Billion in Sales Expected for Biogen (BIIB) This Quarter
www.americanbankingnews.com - April 27 at 2:38 AM |
 | Brian Skorney on Biogen Earnings
www.bloomberg.com - April 26 at 5:19 PM |
| Analyst Recommendations for Biogen in April
finance.yahoo.com - April 26 at 5:19 PM |
| FY2020 EPS Estimates for Biogen (BIIB) Lowered by Analyst
www.americanbankingnews.com - April 26 at 11:28 AM |
| FY2020 EPS Estimates for Biogen Boosted by William Blair (BIIB)
www.americanbankingnews.com - April 26 at 11:28 AM |
| Biogen's (BIIB) Neutral Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 26 at 10:32 AM |
| Jefferies Group Weighs in on Biogen's Q3 2018 Earnings (BIIB)
www.americanbankingnews.com - April 26 at 9:50 AM |
| Piper Jaffray Analysts Reduce Earnings Estimates for Biogen (BIIB)
www.americanbankingnews.com - April 26 at 9:24 AM |
| 3 Things In Biotech, April 25: Biogen Advances, Prothena Crashes, Lilly Survives
seekingalpha.com - April 26 at 8:14 AM |
| Blog Exposure - Galapagos Commenced First Clinical Trial FALCON with Investigational Triple Combination Therapy in Cystic Fibrosis Patients
finance.yahoo.com - April 26 at 8:14 AM |
| Biogen’s Fampyra and Interferons in 1Q18
finance.yahoo.com - April 26 at 8:14 AM |
 | Biotech Bounceback: Amgen, Biogen Gain Believers
www.barrons.com - April 25 at 5:30 PM |
| Biogen Q1 2018: Too Cheap To Ignore
seekingalpha.com - April 25 at 5:30 PM |
Biogen (NASDAQ:BIIB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement
Biogen (NASDAQ BIIB) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
